Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study

Carrato, Alfredo; Köhne, C.-H.; Bedenne, Laurent; Popov, I. B.; Bouché, Olivier; Gaspar, Eugenio Marcuello; Rougier, Philippe; Schubert, U.; Biertz, F.; Becker, H.

doi:10.1200/jco.2006.24.18_suppl.3563

Cited by 8 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: History Of Adjuvant Treatment With Evolution Of 5-fumentioning

confidence: 97%

Use of capecitabine in management of early colon cancer

Hameed¹,

Cassidy²

2011

CMR

View full text Add to dashboard Cite

Capecitabine (Xeloda®, Roche, Basel, Switzerland) is a pro-drug of 5-fluorouracil (5-FU), and it is converted to 5-FU in the cancer cell by enzymatic degradation. The role of capecitabine in colorectal cancer has evolved in the last 15 years. In early trials in the metastatic setting, capecitabine has shown superior response rates compared with those achieved with 5-FU (Mayo Clinic regimen) (26% vs 17%), with equivalent progression-free survival and overall survival. In the adjuvant setting, the Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial demonstrated that capecitabine as a single agent led to improvement in relapse-free survival (hazard ratio: 0.86, 95% confidence interval: 0.74–0.99, P = 0.04) and was associated with significantly fewer adverse events than 5-FU plus leucovorin (LV, folinic acid). On the basis of the X-ACT trial, capecitabine was approved by the United States Food and Drug Administration, the National Institute for Clinical Excellence, and the Scottish Medicines Consortium as monotherapy for the adjuvant treatment of stage III colon cancer. The next step was to incorporate capecitabine into combination therapy. The XELOXA trial studied the combination of capecitabine and oxaliplatin (XELOX) vs 5-FU/LV and demonstrated 5-year disease-free survival of 66% for XELOX, compared with 60% for 5-FU/LV. The toxicity profile was also quite comparable in the two arms. So both the single agent use of capecitabine as well as in combination with oxaliplatin can be considered as part of the standard of care in management of early colon cancer in appropriately selected patient groups.

show abstract

Section: History Of Adjuvant Treatment With Evolution Of 5-fumentioning

confidence: 97%

Use of capecitabine in management of early colon cancer

Hameed¹,

Cassidy²

2011

CMR

View full text Add to dashboard Cite

show abstract

“…However the toxicity profile favored the infusional regimen with lesser incidence of grade III/IV diarrhea, neutropenia, and mucositis. 13 Similarly, trials did not show any survival benefit of high dose LV compared with low dose LV in combination with 5-FU. 8 At the same time, oxaliplatin and irinotecan were showing activity and potential roles in management of colon cancer.…”

Section: History Of Adjuvant Treatment With Evolution Of 5-fumentioning

confidence: 97%

Use of capecitabine in management of early colon cancer

Cassidy¹,

Hameed²

2011

CMAR

View full text Add to dashboard Cite

Capecitabine (Xeloda ® , Roche, Basel, Switzerland) is a pro-drug of 5-fluorouracil (5-FU), and it is converted to 5-FU in the cancer cell by enzymatic degradation. The role of capecitabine in colorectal cancer has evolved in the last 15 years. In early trials in the metastatic setting, capecitabine has shown superior response rates compared with those achieved with 5-FU (Mayo Clinic regimen) (26% vs 17%), with equivalent progression-free survival and overall survival. In the adjuvant setting, the Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial demonstrated that capecitabine as a single agent led to improvement in relapse-free survival (hazard ratio: 0.86, 95% confidence interval: 0.74-0.99, P = 0.04) and was associated with significantly fewer adverse events than 5-FU plus leucovorin (LV, folinic acid). On the basis of the X-ACT trial, capecitabine was approved by the United States Food and Drug Administration, the National Institute for Clinical Excellence, and the Scottish Medicines Consortium as monotherapy for the adjuvant treatment of stage III colon cancer. The next step was to incorporate capecitabine into combination therapy. The XELOXA trial studied the combination of capecitabine and oxaliplatin (XELOX) vs 5-FU/LV and demonstrated 5-year disease-free survival of 66% for XELOX, compared with 60% for 5-FU/LV. The toxicity profile was also quite comparable in the two arms. So both the single agent use of capecitabine as well as in combination with oxaliplatin can be considered as part of the standard of care in management of early colon cancer in appropriately selected patient groups.

show abstract